Last update 01 Nov 2024

MWN-101

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Target
GCGR x GIPR x GLP-1R
Mechanism
GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus, Type 2Obesity
Inactive Indication-
Originator Organization
Shanghai Minwei Biotechnology Co., Ltd
Active Organization
Shanghai Minwei Biotechnology Co., Ltd
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with MWN-101
CTR20240817 / Active, not recruitingPhase 2
评价MWN101注射液治疗2型糖尿病的有效性、安全性及药代动力学特征的随机、双盲、安慰剂及阳性药平行对照、多中心Ⅱ期临床研究
[Translation] A randomized, double-blind, placebo- and active drug-controlled, multicenter phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN101 injection in the treatment of type 2 diabetes
CTR20240802 / Active, not recruitingPhase 2
评价MWN101注射液在非糖尿病的超重或肥胖受试者中的有效性、安全性及药代动力学特征的随机、双盲、安慰剂平行对照、多中心II期临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN101 injection in non-diabetic overweight or obese subjects
CTR20231757 / CompletedPhase 1
评估MWN101注射液在中国健康志愿者中单、多次皮下给药的安全性、耐受性、药代动力学的随机、双盲、安慰剂对照、剂量递增Ia期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalation Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetics of MWN101 injection after single and multiple subcutaneous administration in healthy Chinese volunteers
100 Clinical Results associated with MWN-101
Login to view more data
100 Translational Medicine associated with MWN-101
Login to view more data
100 Patents (Medical) associated with MWN-101
Login to view more data
100 Deals associated with MWN-101
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
CN
Shanghai Minwei Biotechnology Co., Ltd
26 Mar 2024
ObesityPhase 2
CN
Shanghai Minwei Biotechnology Co., Ltd
25 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free